Intrinsic Imaging Awarded Phase II Clinical Trial for Advanced Squamous Cell Carcinoma

International Phase II clinical trial assessing a new treatment for advanced squamous cell carcinoma.

Boston, MA

March 31, 2015 — Intrinsic Imaging announced that it has been awarded an international Phase II clinical trial to assess a new treatment for patients with advanced squamous cell carcinoma (SCC).

Intrinsic Imaging will provide comprehensive imaging core lab services including, but not limited to, protocol and imaging charter development, site qualification, site training and management, image transfer, blinding and processing of images acquired by computed tomography (CT) or magnetic resonance imaging (MRI). Subsequently, study treatment response will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) evaluation criteria.

About Intrinsic Imaging, LLC

Intrinsic Imaging is an ISO certified medical imaging CRO and imaging core lab providing comprehensive services in support of Phase I-IV clinical trials and Class I, II, III medical device trials. Intrinsic Imaging is also a world leader in conducting Artificial Intelligence studies. With its team of more than 650 board-certified and fellowship-trained physicians, Intrinsic Imaging's team has sub-specialization in all therapeutic areas, including Cardiovascular, Central Nervous System,Gastroenterology, Musculoskeletal, Oncology and Ophthalmology. Certified by the British Standards Institution (BSI), Intrinsic Imaging is the only company in the world to hold five ISO certifications specifically for providing imaging core lab services on clinical trials. For more information, please visit www.IntrinsicImaging.com.

Contact:

Intrinsic Imaging, LLC
580 Main St., Suite 210
Bolton, MA, 01740, USA
+1 978-616-4650
Contact@IntrinsicImaging.com